Byungje Sung

This inventor holds 9 USPTO granted patents and 10 published patent applications, plus 2 CIPO patents and 1 EPO patent. Top assignees: Abl Bio Inc., I-Mab Biopharma US Limited, Legochem Biosciences, Inc.. Active years: 2022-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Byungje Sung. Retrieved from https://idiyas.com/inventor/byungje-sung

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 9 (Patent Applications = 10)

% Patents Active = 100.0

CIPO Patents = 2 (Patent Applications = 8)

EPO Patents = 1 (Patent Applications = 16)

Average Co-Inventor Count = 12.5

ph-index = 1

Forward Citations = 3(Granted Patents)

Location History:

Daejeon, KR (2023)
Seongnam-Si, KR (2022 - 2024)

Company Filing History:

I-Mab Biopharma US Limited

patents

1 out of 25

Legochem Biosciences, Inc.

patents

where one patent can have more than one assignee

Years Active: 2022-2026

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12624110 - ANTIBODY TO INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (IGF1R) AND RELATED COMPOSITIONS AND USES (2026-05-12),

2. 12577313 - ANTI-CLAUDIN 18.2 AND ANTI-4-1BB BISPECIFIC ANTIBODIES AND USES THEREOF (2026-03-17),

3. 12195537 - Anti-4-1BB antibody and use thereof (2025-01-14),

4. 12122830 - Anti-ROR1 antibody and use thereof (2024-10-22),

5. 12071483 - Bispecific antibody to alpha-synuclein/insulin-like growth factor 1 receptor and use thereof (2024-08-27),

6. 12049493 - Anti-alpha-synuclein antibodies and uses thereof (2024-07-30),

7. 11891445 - Anti-B7-H3 antibody and use thereof (2024-02-06),

8. 11707533 - Antibody-drug conjugate comprising antibody against human ROR1 and use for the same (2023-07-25),

9. 11261259 - Anti-claudin 18.2 and anti-4-1BB bispecific antibodies and uses thereof (2022-03-01),

Title: Byungje Sung: Trailblazer in Antibody Innovations

Introduction

Byungje Sung, located in Seongnam-si, South Korea, is a prominent inventor known for his significant contributions to the field of biotechnology. With a total of seven patents to his name, Sung's innovative work primarily focuses on developing antibodies for targeted cancer therapies, showcasing his commitment to advancing medical science.

Latest Patents

Sung's most recent patents include the development of an anti-4-1BB antibody, which has potential applications in immunotherapy. This invention provides a novel approach to cancer treatment by utilizing an anti-4-1BB antibody or its antigen-binding fragment. Furthermore, he has also introduced an anti-ROR1 antibody that specifically recognizes human and mouse ROR1. This monoclonal antibody can be effectively employed in cancer targeting treatments, aiding in the detection of various cancers expressing ROR1 through specific binding. Additionally, this therapeutic agent shows promise in tumor inhibition and targeted drug delivery.

Career Highlights

Throughout his career, Byungje Sung has been associated with leading companies in the biopharmaceutical sector, including Abl Bio and I-Mab Biopharma US Limited. His work at these organizations has significantly contributed to advancements in cancer targeting therapies. Sung’s expertise and inventive spirit continue to influence his field positively.

Collaborations

Byungje Sung has collaborated with notable professionals, including Eunsil Sung and Yeunju Kim. These partnerships have fostered a collaborative atmosphere that has led to groundbreaking innovations in antibody research and development.

Conclusion

With his impressive portfolio of patents and his dedication to improving cancer treatment options through innovative antibody technologies, Byungje Sung stands out as a pivotal figure in biotechnology. His ongoing contributions will undoubtedly have far-reaching effects on future medical therapies and patient care.

Profile summary based on public USPTO records.